Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
This study has been terminated.
Study NCT01179737   Information provided by Novartis

First Received on August 3, 2010.   Last Updated on March 25, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pulmonary Arterial Hypertension
Additional conditions recognized in this trial
Hypertension
Hypertension, Pulmonary
More general conditions related to this trial
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Interventions listed in this trial
Nilotinib 50 mg
Nilotinib 150mg
Nilotinib 300mg
Nilotinib placebo
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services